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Transforming growth factor-b1 (TGF-b1) is known to induce
progression of experimental renal disease. Here we
determined whether there is an association between serum
levels of TGF-b1 and the risk factors for progression of
clinically relevant renal disorders in 186 black and 147 white
adults, none of whom had kidney disease or diabetes. Serum
TGF-b1 protein levels were positively and significantly
associated with plasma renin activity along with the systolic
and diastolic blood pressure in blacks but not whites after
controlling for age, gender, and body mass index. These
TGF-b1 protein levels were also significantly associated with
body mass index and metabolic syndrome and more
predictive of microalbuminuria in blacks than in whites. The
differential association between TGF-b1 and renal disease risk
factors in blacks and whites suggests an explanation for the
excess burden of end-stage renal disease in the black
population, but this requires validation in an independent
cohort. Whether these findings show that it is the circulating
levels of TGF-b1 that contribute to renal disease progression
or the findings reflect other unmeasured factors, further
longitudinal studies are needed.
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Transforming growth factor b1 (TGF-b1), a prominent
member of a superfamily of proteins, regulates cell growth
and differentiation, inflammation and immunity.1 TGF-b1 is
a fibrogenic cytokine that plays a key role in the pathogenesis
of renal disease, and TGF-b1 blockade may prevent renal
disease progression.2,3
Blockade of the renin angiotensin system (RAS) is an
important therapeutic strategy for prevention of the
progression of renal disease,4–6 and experimental as well as
clinical studies have shown that the benefits of RAS blockade
may be in part related to the strong bidirectional relationship
between RAS and TGF-b.7–12 Antonipillai et al.8 reported that
TGF-b1, at picomolar concentrations, promotes the secretion
of renin by rat juxtaglomerular cells. Brezniceanu et al.9
showed that active human TGF-b1 induces angiotensinogen
gene expression in murine proximal tubular epithelial
cells. It has also been reported that both renin and
angiotensin II stimulate TGF-b1 expression. Huang et al.10
demonstrated that human or rat recombinant renin, at
physiological concentrations, induces TGF-b1 and other
members of the fibrotic cascade in human/rat mesangial
cells through a renin receptor dependent and enzymatic and
angiotensin II independent, mechanism. Wolf et al.11 re-
ported that addition of angiotensin II to murine proximal
tubular (MCT) cells induced TGF-b1 mRNA expression and
synthesis and release of active TGF-b1 protein and that the
growth promoting effects of angiotensin II on the cultured
murine proximal tubular cells can be accomplished with the
addition of TGF-b1 to the murine proximal tubular cells. In
the clinical setting, drugs which block the RAS and prevent
renal disease progression reduce serum levels of TGF-b1
protein.12
Hypertension affects over 1 billion individuals worldwide
and is a leading risk factor for end-stage kidney disease
(ESRD).13,14 Hypertension is more prevalent in blacks, and
renal disease progression and ESRD are more frequent in
blacks compared to other ethnic/racial groups.15–17
We have reported that blacks with hypertension and ESRD
have higher circulating levels of TGF-b1 protein compared to
whites.18,19 One potential explanation for the excess burden
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of ESRD in blacks is an increased level and/or biologic
activity of TGF-b1 in blacks compared to whites.
In this study, we investigated the association between
TGF-b1 protein levels and risk factors for renal disease
progression in adult black or white subjects and report that
peripheral blood TGF-b1 protein levels are positively
associated with plasma renin activity (PRA), systolic blood
pressure, diastolic blood pressure, BMI and metabolic
syndrome (MBS)20 in blacks, but not in whites. We also
report that TGF-b1 protein levels are more predictive of
microalbuminuria in blacks than in whites.
RESULTS
Study participants
The demographic and clinical characteristics of study
participants, stratified by race and hypertension status, are
shown in Table 1. The mean (±s.d.) age of the 333 study
subjects was 45.2±10.6 years, and there were 186 blacks and
147 whites; the black participants were 4.7 years younger
(P¼ 0.0001) and more frequently female (P¼ 0.005). The
mean (±s.d.) BMI was high in both groups (29.3±6.1 kg/m2
for the entire cohort), but higher in blacks than whites (30.0
vs 28.4 kg/m2, P¼ 0.01) and higher in female than male
participants (29.8 vs 28.5 kg/m2, P¼ 0.05). The differences
between black and white subsamples with respect to the
percentages of individuals classified as overweight (25–30 kg/
m2) or obese were not significant (X30 kg/m2) (P¼ 0.14). In
this group 37.6% of the blacks and 46.3% of the whites were
hypertensive as defined by average clinic BPX140/90 mm Hg
or being on antihypertensive medication (P¼ 0.11); 74% of
the hypertensives had stage 1 hypertension (140–159/
90–100 mm Hg), and 54% of hypertensives were on treatment
for hypertension when they enrolled in the study; the latter
were withdrawn from all antihypertensive medications for a
minimum of two weeks prior to evaluation and collection of
biologic specimens for laboratory studies including the
serum collection for measure TGF-b1 concentration. The
black and white participants had similar 24-h urine sodium
excretion, urinary albumin to creatinine excretion ratio, and
prevalence of metabolic syndrome.
TGF-b1, PRA, and sodium excretion. Serum total (active
plus latent) TGF-b1 protein levels were measured in 333
adults (186 blacks and 147 whites) without kidney disease or
diabetes, and were higher in blacks compared to whites,
higher in hypertensives than in normotensives, and highest in
black hypertensives (Table 1, P¼ 0.01), confirming and
extending our earlier findings from an independent
study comprised of 61 hypertensives and 90 normal
controls.19 In this and all subsequent analyses, TGF-b1
protein levels were square-root transformed to reduce the
substantial positive skew and make the distribution approxi-
mately normal. The 10th and 90th percentiles of TGF-b1
protein concentration in the full sample were 26.52 and
55.12 ng/ml, respectively.
We also measured active TGF-b1 protein concentration in
sera from 147 of the 333 subjects assayed for total TGF-b1
protein. The 147 specimens were selected on the basis of their
availability. We found that 93% of the clinical specimens did
not have measurable levels of active TGF-b1 protein, and the
mean (±s.e.) level was 12.45±2.32 ng/ml in the 11 (7%)
Table 1 | Characteristics of subjects, stratified by race and hypertension statusa
Black subjects White subjects
Variable Normotensive (n=116) Hypertensive (n=70) Normotensive (n=79) Hypertensive (n=68) P-valueb
Sex (% male) 37.1 21.4 40.5 52.9 0.002
Age (year) 40.7±9.1 47.1±10.7 46.1±10.9 49.9±9.9 0.0001
BMI (kg/m2)c 29.4±6.6 31.2±6.1 27.4±5.5 29.4±5.5 0.004
Systolic BP (mm Hg)d 117±12 148±15 114±12 141±16 0.0001
Diastolic BP (mm Hg)d 75±8 91±9 75±8 90±9 0.0001
Plasma glucose (mg 100 ml) 80.9±23.6 81.4±15.2 80.1±29.7 80.8±20.3 0.99
Serum creatinine (mg 100 ml) 0.92±0.22 0.88±0.18 0.86±0.18 0.87±0.20 0.18
PRA (ng/ml per h) 1.3±1.4 0.8±1.1 2.1±1.5 1.7±1.6 0.0001
Median (25th, 75th percentiles) 1.0 (0.3, 1.7) 0.3 (0.2, 1.1) 1.8 (1.0, 2.7) 1.2 (0.7, 2.1)
Urinary Na Excretion (mEq/24 h) 144±73 128±58 150±74 140±57 0.32
Urinary albumin/creatinine ratio (mg/g) 9.1±11.4 16.9±35.7 8.6± 8.9 20.3± 61.6 0.001
Median (25th, 75th percentiles) 5.0 (3.7, 8.3) 7.9 (5.5, 15.0) 6.2 (4.5, 8.8) 7.5 (4.8, 12.5)
Microalbuminuria (%) 3.9 9.2 2.7 7.8 0.27
Metabolic syndrome (%)e 4.6 17.2 6.4 22.1 0.0008
Number of metabolic syndrome criteria 1.1±1.1 2.0±0.9 1.0±1.0 1.9±1.0 0.001
TGF-b1 protein (ng/ml) 42±15 46±19 38±14 42±14 0.01
Median (25th, 75th percentiles) 41 (33, 49) 42 (36, 53) 39 (30, 45) 40 (34, 46)
aPlus–minus values are mean±s.d.
bP-value based on F-test for 1-way analysis of variance for continuous variables (after log-transforming PRA and urinary albumin/creatinine ratio and square-root-transforming
TGF-b1 protein) or w2 test of independence for binary variables.
cHeight and weight were measured two times. Body mass index (BMI) was calculated as average weight (kilograms) divided by the square of average height (meters).
dBlood pressure was measured with a mercury sphygmomanometer using standard American Heart Association Guidelines, with subjects in the seated position and arm at
heart level. Three readings were obtained and their average was treated as blood pressure measure. Hypertension status was defined as an average BP X140/90 mm g or
being on antihypertensive medication. Individuals taking medication were withdrawn successfully from medication for at least 2 weeks before the study. Those whose BP
exceeded 160/105 mm Hg, before or after being withdrawn from medication, were not eligible.
eMetabolic syndrome was defined according to the current recommended criteria of the National Cholesterol Education Program (Adult Treatment Panel (ATP) III).16
Kidney International (2009) 76, 72–80 73
M Suthanthiran et al.: Circulating transforming growth factor-b1 levels o r i g i n a l a r t i c l e
specimens that were positive. Among the sera tested for
active TGF-b1 protein, measurable levels of active TGF-b1
were observed in two of 35 black normotensives (5.7%,
11.89±1.64 ng/ml), 4 of 56 black hypertensives
(7.1%, 6.71±3.57), 2 of 30 white normotensives, (6.7%,
13.59±1.44 ng/ml), and 3 of 37 white hypertensives (8.1%,
19.75±4.75 ng/ml).
PRA was lower in blacks compared with whites (Table 1,
P¼ 0.0001), an observation that has also been made by
others.21 Among the four groups shown in Table 1, PRA was
lowest in black hypertensives compared to the three other
groups, consistent with previous reports of a low-renin
profile in black hypertensives.21
TGF-b1 protein concentration was positively associated
with (log-transformed) PRA in the entire cohort (P¼ 0.005,
adjusted for race, sex, age, and BMI); however, addition of a
race-by-TGF-b1 protein interaction term revealed that this
association was only present in blacks, with those at the 90th
percentile predicted to have 3.24 [¼ exp(1.17), P¼ 0.0001]
times the level of PRA as those at the 10th percentile of
protein; the projected ratio of PRA between whites at the
two extreme deciles was only 1.09 [¼ exp(0.09), P¼ 0.71]
(Table 2A). The difference between blacks and whites in the
relationship of PRA to TGF-b1 protein concentration was
significant (Table 2A, P¼ 0.0007 for the race-by-TGF-b1
protein interaction term).
The bivariate relationship between PRA and TGF-b1
protein concentration, without adjustment for sex, age, or
BMI, is shown in Figure 1a (blacks) and Figure 1b (whites).
The difference in PRA between blacks and whites is large
at low values of TGF-b1, and negligible at high values of
TGF-b1 protein concentration.
As noted above, 24-h urinary sodium excretion rate was
not different between blacks and whites (P¼ 0.32). However,
although TGF-b1 protein concentration exhibited a non-
significant negative association with sodium excretion in
blacks and a non-significant positive association in whites
(Table 2A), the difference in the association between blacks
and whites, controlling for sex, age, and BMI, was nearly
significant (P¼ 0.06).
TGF-b1 and blood pressure
TGF-b1 protein concentration, adjusted for race, sex, age,
and BMI, was weakly associated with systolic blood
pressure in the group as a whole (6.4 mm Hg inter-decile
difference (IDD¼ predicted difference between those at the
90th and 10th percentiles of TGF-b1 protein concentration),
P¼ 0.02), but addition of the race interaction term again
revealed that this association was primarily evident in black
and not white subjects (IDD¼ 9.5 mm Hg; P¼ 0.009 for
blacks; IDD¼ 2.3 mm Hg; P¼ 0.58 for whites; Table 2A and
Figure 2a and b). This race-dependent association was also
observed for diastolic blood pressure (IDD¼ 4.7 mm Hg;
P¼ 0.03 for blacks; IDD¼ 1.5 mm Hg; P¼ 0.56 for whites;
Figure 2c and d). For both systolic and diastolic measures,
the covariate adjusted relationship of clinic blood pressure
with TGF-b1 protein was more than three times greater in
blacks compared to whites, although the difference between
racial groups (interaction term) was not statistically sig-
nificant (Table 2A). Mean arterial pressure exhibited the same
pattern as systolic and diastolic blood pressure (not shown).
Pulse pressure was also related to TGF-b1 protein in blacks
(P¼ 0.05), but not in whites (P¼ 0.77).
Table 2 | (A) Predicted difference (SE) in outcomes between
subjects at the 90th percentile and subjects at the 10th
percentile of TGF-b1 protein distributiona and (B) Predicted
Odds Ratio (95 % CI) for microalbuminuria or metabolic
syndrome between subjects at the 90th percentile and
subjects at the 10th percentile of TGF-b1 protein
distributiona
Outcome Black subjects
White
subjects
Race-by-TGF-
b1 interaction
P-value
(A)
PRA (ng/ml per h)b 1.17 (0.21) 0.09 (0.24)
P-value 0.0001 0.71 0.0007
Urine Na excretion
(mEq/24 h)b
18.8 (14.0) 20.0 (15.7)
P-value 0.18 0.20 0.06
Systolic BP (mm Hg)b,c 9.5 (3.6) 2.3 (4.2)
P-value 0.009 0.58 0.20
Diastolic BP (mm Hg)b,c 4.7 (2.2) 1.5 (2.5)
P-value 0.03 0.56 0.34
Pulse pressure (mm Hg)b,c 4.8 (2.4) 0.8 (2.8)
P-value 0.05 0.77 0.29
BMI (kg/m2)b,d 2.5 (1.1) 1.2 (1.3)
P-value 0.03 0.36 0.47
Number of metabolic
syndrome criteria (0–5)e,f
0.82 (0.21) 0.42 (0.23)
P-value 0.0001 0.07 0.20
(B)
Urine albumin: creatinine
ratio X30 mg/gmg
6.6 (1.4, 31.1) 2.4 (0.3, 19.0)
P-value 0.02 0.39 0.45
Metabolic syndromee,g 4.5 (1.0, 19.9) 3.0 (0.8, 11.6)
P-value 0.04 0.11 0.69
aEach outcome was analyzed in a regression analysis performed on the full sample
that included race, log-transformed TGF-b1 protein, and a race-by-TGF-b1
interaction term while controlling for sex and age; analyses, except those predicting
BMI and metabolic syndrome, also controlled for BMI.
bOrdinary linear regression analysis.
cBlood pressure was measured with a mercury column using standard American
Heart Association Guidelines, with subjects in the seated position and arm at heart
level. Three readings were obtained and their average was treated as the blood
pressure measure.
dHeight and weight were measured two times. Body mass index (BMI) was
calculated as average weight (kilograms) divided by the square of average height
(meters).
eMetabolic syndrome was defined according to the current recommended criteria of
the National Cholesterol Education Program (Adult Treatment Panel (ATP) III).20
fOrdered probit regression analysis.
gLogistic regression analysis.
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TGF-b1 and microalbuminuria
Six percent of blacks and 5.1% of whites had microalbumi-
nuria. As expected, the proportion with microalbuminuria
was higher in hypertensives compared with normotensives
(Table 1), although the majority of these mild hypertensives
did not have microalbuminuria. Controlling for sex, race,
age, and BMI in a logistic regression analysis, TGF-b1 was
significantly associated with microalbuminuria overall in
blacks, but not in whites. The predicted odds ratio for the
presence of microalbuminuria between a black subject at the
90th percentile compared to someone at the 10th percentile
of TGF-b1 protein levels was 6.6 (95% CI: 1.4, 31.1;
P¼ 0.02), whereas for whites it was 2.4 (95% CI: 0.3, 19.0;
P¼ 0.39) (Table 2B). Despite the association being substan-
tially stronger in blacks than in whites, the interaction was
not statistically significant (Table 2B, P¼ 0.45).
TGF-b1 and BMI
TGF-b1 was positively associated with BMI, controlling for
race, sex, and age, overall (B¼ 2.0 kg/m2 IDD, P¼ 0.02), and
for blacks (B¼ 2.5 kg/m2 IDD, P¼ 0.03) but not whites
(B¼ 1.2 kg/m2 IDD, P¼ 0.36) (Table 2A and Figure 3a and
b). The relationship of TGF-b1 to BMI was two times as
strong for blacks as for whites, but the difference was not
statistically significant (Table 2A, P¼ 0.47 for the race
interaction term).
TGF-b1 and metabolic syndrome
Subjects were characterized based on the number of features
(0–5) of MBS (elevated BP, increased waist circumference,
elevated triglycerides, elevated fasting glucose, and low HDL
cholesterol) present, and also whether they had three or more
criteria for MBS. There was little difference between the
blacks and whites in either the number of features of MBS or
the proportion of participants with three or more criteria for
MBS. TGF-b1 protein levels were significantly associated with
number of features of MBS (in an ordered probit analysis) as
well as the presence of MBS (logistic analysis), controlling for
sex, age, and race. Inclusion of the race interaction term again
revealed that the association with number of MBS features
was strong in blacks (P¼ 0.0001), but only marginal in
whites (P¼ 0.07, Table 2A). Similarly, the predicted odds of
meeting criteria for MBS (having three or more criteria) was
4.5 (95% CI: 1.0, 19.9; P¼ 0.04; Table 2B) for blacks at the
90th percentile of TGF-b1 concentration compared to those
at the 10th percentile, and 3.0 (0.8, 11.6; P¼ 0.11) for whites.
The associations in blacks were stronger, but not significantly
stronger, than those in whites (Table 2A and B).
DISCUSSION
Hypertension and ESRD are increasing in prevalence world-
wide, and both conditions are more common in blacks
compared to whites.24 We report a positive association,
primarily in blacks, between circulating TGF-b1 protein
concentration and plasma renin activity, blood pressure,
microalbuminuria, BMI, and MBS. Our findings suggest that
TGF-b1, a known mediator of renal disease, may modulate
multiple renal risk factors, and may be biologically more
active in blacks compared to whites.
An earlier study has shown that TGF-b1, at picomolar
concentrations, induces the secretion of renin by rat renal
juxtaglomerular cells.8 Our study showing that TGF-b1 levels
are positively associated with PRA, to the best of our
Black subjects (n=151)
White subjects (n=138)
PR
A 
(ng
/m
l p
er 
h, 
na
tur
al 
log
)
PR
A 
(ng
/m
l p
er 
h, 
na
tur
al 
log
)
TGF-β1 protein (ng/ml, square root transformed)
TGF-β1 protein (ng/ml, square root transformed)
r =0.03, P=0.72
r =0.37, P=0.0001
1 2 3 4 5 6 7 8 9 10 11 12
1 2 3 4 5 6 7 8 9 10 11 12
2
1
0
–1
–2
–3
–1
–2
–3
3
2
1
0
3
Figure 1 | Bivariate relationship of peripheral blood
transforming growth factor b1 protein concentration to
plasma renin activity in black and white subjects. Peripheral
blood total transforming growth factor b1 (TGF-b1, ng/ml) level
was measured after acid activation and neutralization of serum
and using an isoform-specific TGF-b1 ELISA. Plasma renin activity
(PRA, ng/ml per h) was measured using an enzyme-based method
and by quantification of generated Ang I by radioimmunoassay.22
Scatterplots show the bivariate relationship of TGF-b1 protein
concentrations to PRA in black subjects (a) and white subjects (b).
TGF-b1 protein measure was transformed using the square root
transformation to reduce the positive skewness and make the
resulting distribution approximately symmetric. PRA was
transformed to natural logarithms (ln) to reduce skewness and
heteroskedasticity. Pearson correlations (r) and their associated
P-values are presented. The three boxes on the regression line
show the predicted value of the outcome variable for subjects at
the 10th, 50th, and 90th percentiles of the overall distribution of
TGF-b1 protein. Numbers in parenthesis are the number of
subjects studied. The symbols ‘o’ and ‘x’ are used to identify
normotensive and hypertensive subjects.
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knowledge, is the first clinical study reporting a positive
relationship between TGF-b1 and the RAS in humans. The
association of TGF-b1 and renin may be mechanistically
relevant for fibrosis, vascular pathology, and the progression
of renal disease.
The positive association between TGF-b1 and PRA in
blacks is intriguing, and may even appear paradoxical, as
PRA levels are lower in blacks compared to whites, and lowest
in the black hypertensives, and serum TGF-b1 levels are
higher in blacks compared to whites and highest in the black
hypertensives. A linear and close looped relationship between
TGF-b1 and PRA in blacks would predict that blacks would
have a higher level of PRA compared to whites. One potential
explanation that can account for the lower PRA in blacks
despite a higher TGF-b1 is that TGF-b1 not only stimulates
renin secretion but also has an additional and stimulatory
effect on sodium reabsorption by the kidney, and the
increased sodium (and water) reabsorption results in renin
suppression and low-renin hypertension (a well documented
form of hypertension in the black population). Partial
support for this concept is provided by our findings that
24 h urine sodium excretion is lowest in the black
hypertensives (Table 1), and the association between 24 h
urine sodium excretion and TGF-b1 protein levels is negative
in blacks and positive in whites (Table 2). Additional
measurements of the response of blood pressure, PRA and
TGF-b1 to salt loading should help clarify our observations.
It is note worthy that TGF-b1 has been reported to increase
the activity of serine/threonine kinase, SGK,25 a kinase
expressed in several tissues26 including the sodium reabsorp-
tion sites in the human kidney.27 Importantly, SGK from
Xenopus as well as from humans has been shown to increase
the activities of the two sodium channels located in the distal
tubule and ascending thick limb of loop of Henle, the
epithelial sodium channel activity and the sodium, potas-
sium, and chloride co-transporter.28,29
The positive association between TGF-b1 and PRA in
blacks may also result from renin or angiotensin II
functioning as the stimulus for TGF-b1 synthesis and
secretion. Huang et al.10 observed that human or rat
recombinant renin, at physiological concentrations, induces
TGF-b1 through a renin receptor-dependent mechanism.
Our study does not resolve whether the observed and positive
association results from TGF-b1 stimulating renin release,
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Figure 2 | Bivariate relationship of clinic systolic and diastolic blood pressure to peripheral blood TGF-b1 protein concentration in
black and white subjects. Peripheral blood total transforming growth factor b1 (TGF-b1, ng/ml) level was measured after acid activation
and neutralization of serum and using an isoform-specific TGF-b1 ELISA, and transformed using the square root transformation to reduce
the positive skewness and make the resulting distribution approximately symmetric. Blood pressure measurements were made with a
mercury column according to American Heart Association Guidelines, with patients in the seated position and arm at heart level.23 Three
readings were obtained and their average was treated as the blood pressure measure. Scatterplots show the bivariate relationship of TGF-
b1 protein concentrations to systolic (a and b) or diastolic (c and d) blood pressure. Pearson correlations (r) and their associated P-values are
presented. The three boxes on the regression line show the predicted value of the outcome variable for subjects at the 10th, 50th, and 90th
percentiles of the overall distribution of TGF-b1 protein. Numbers in parenthesis are the number of subjects studied. The symbols ‘o’ and ‘x’
are used to identify normotensive and hypertensive subjects.
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renin or Ang II inducing TGF-b1 secretion, or due to mutual
stimulation as documented in pre-clinical models.7–11
Irrespective of the directionality, it is worth emphasizing
that the positive association between TGF-b1 and renin was
observed only in blacks and not in whites.
Experimental studies suggest a causative role for TGF-b in
vascular remodeling, blood pressure regulation, and renal
disease progression.30 Anti-TGF-b antibodies lower blood
pressure, reduce proteinuria and prevent renal function
decline in rats.31 Deletion of the gene for Emilin-1, a negative
regulator of TGF-b1, results in greater availability of TGF-b1,
increased peripheral vascular resistance, and increased blood
pressure in mice.32 Moreover, inactivation of a single TGF-b1
allele normalizes blood pressure in the Emilin-deficient
mice.32 Our new observations, in addition to confirming
and extending a quantitative difference in TGF-b1 protein
levels between normotensives and hypertensives, advances
the hypothesis that a qualitative difference may exist between
blacks and whites in the association between TGF-b1 levels
and blood pressure.
Body mass and blood pressure are positively associated in
both blacks and whites; however, the age-adjusted prevalence
of hypertension is greater in blacks compared to whites for
BMI ranging from 18.5 to greater than 31.33 The association
of TGF-b1 with both blood pressure and BMI in blacks may
partially explain the increased risk of hypertension for a given
level of BMI in blacks, as well as previously reported
associations between BMI and ESRD.34,35
MBS, a proinflammatory and prothrombotic disorder,
increases the risk for cardiovascular disease as well as kidney
failure.23 Neither the average number of criteria for MBS nor
the prevalence of metabolic syndrome differed between
blacks and whites in our study, but the positive association
of TGF-b1 concentration with both prevalence of MBS and
the number of features of MBS was observed only in blacks.
TGF-b1 increases plasminogen activator inhibitor (PAI)1
production,22 a causal factor in the development of insulin
resistance, type II diabetes, and associated cardiovascular
complications. On the other hand, adipose tissue is a source
of increased TGF-b1 production36 and TGF-b1 concentration
is greater in obese compared with non-obese hyperten-
sives.37,38 Regardless of the direction of the relationship
between TGF-b1 and MBS, TGF-b1 may be a potentially
modifiable target, as well as a novel candidate genetic locus
and biomarker for these important conditions, and may
contribute to increased complications associated with
diabetes in blacks compared to other groups.
Microalbuminuria may reflect generalized endothelial cell
dysfunction as well as early renal injury. TGF-b1 concentra-
tion was positively associated with microalbuminuria only in
blacks and not in whites. Our finding suggests a mechanism
for the greater prevalence of hypertension associated renal
damage in blacks compared to whites as well as an additional
pharmacologic target for reducing albuminuria. Previous
studies have indeed suggested that beneficial effects of RAS
inhibition on preventing renal disease progression may be
mechanistically linked both to lowering TGF-b1 levels and
reducing proteinuria.12,39
Our study has a number of limitations. Both the utility of
characterizing populations based on racial/ethnic categories
as well as the validity of self-identified race/ethnicity for
stratifying populations in clinical studies have been chal-
lenged. In this regard, we note that racial and ethnic
differences exist in the development of ESRD in the
USA.15,16 With respect to the validity of self-identified race/
ethnicity, Tang et al.40 have recently analyzed genetic data for
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Figure 3 | Bivariate relationship of body mass index to
peripheral blood TGF-b1 protein concentration in black and
white subjects. Peripheral blood total transforming growth factor
b1 (TGF-b1, ng/ml) level was measured after acid activation and
neutralization of serum and using an isoform-specific TGF-b1
ELISA, and transformed using the square root transformation to
reduce the positive skewness and make the resulting distribution
approximately symmetric. Height and weight were measured two
times. Body mass index (BMI) was calculated as average weight
(kilograms) divided by the square of average height (meters).
Scatterplots show the bivariate relationship of TGF-b1 protein
concentrations to BMI in black subjects (a) and white subjects (b).
Pearson correlations (r) and their associated P-values are
presented. The three boxes on the regression line show the
predicted BMI for subjects at the 10th, 50th, and 90th percentiles
of the overall distribution of TGF-b1 protein. Numbers in
parenthesis are the number of subjects studied. The symbols ‘o’
and ‘x’ are used to identify normotensive and hypertensive
subjects.
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326 microsatellite markers that were typed uniformly in a
large multiethnic population (n¼ 3636) and found a near-
perfect correspondence of genetic cluster analysis of micro-
satellite markers with the four self-reported race/ethnicity
categories, white, African American, East Asian, and
Hispanic.
Our investigation can also be criticized for not ascertain-
ing TGF-b1 availability at the tissue/cellular level in view of
the substantial post-translational regulation of TGF-b1
bioactivity,41 and differential tissue availability remains a
plausible mechanism for our observations. In this regard,
Huang et al.42,43 have reported renal protection by latent
TGF-b in experimental mouse models of ureteral obstruction
and crescentric glomerulonephritis. The intriguing hypoth-
esis that the active version is pathogenetic whereas an excess
of latent form is protective merits investigation in the clinic.
We measured active as well as latent TGF-b1 in sera from a
subset of subjects assayed for total TGF-b1 (active plus
latent). Our observations that the active version is found in
only 7% of peripheral blood specimens, and with similar
frequencies in normotensives and hypertensives suggest that
the presence or absence of the latent form is unlikely to
explain the associations observed in our study.
In summary, we find positive associations of TGF-b1 with
PRA, blood pressure, BMI, metabolic syndrome, and
microalbuminuria, primarily in black subjects with either
normal blood pressure or mild hypertension, and not in
white subjects with similar clinical characteristics. Our
findings suggest that the biologic activity of TGF-b1 is
higher in blacks compared to whites. Should the significant
association between TGF-b1 and mediators of renal disease
in blacks be validated in an independent cohort, a new and
targetable mechanism for the rapid progression and the
excess burden of ESRD in the black population would
emerge.
METHODS
Study participants
We studied 333 black and white subjects with or without mild
hypertension, and without overt kidney disease or cardiovascular
disease. The study participants are from a cross-sectional study of
race/ethnicity and blood pressure, The Neighborhood Study of
Blood Pressure and Sleep44 was conducted from 1999 through 2003
at four New York City institutions – Weill Cornell Medical College,
Mount Sinai School of Medicine, Harlem Hospital, and the North
General Hospital – using a common protocol. The study protocol
and consent form were approved by the institutional review
committees for human subject research at each institution.
Participants were 18–65 years of age, had no known cardiovas-
cular disease or diabetes, and had no medical problems other than
hypertension. Participants were asked to self-report their ethnic
group/race. The mutually exclusive categories were ‘Black’, ‘White’,
‘Asian’ or ‘Othery please specify’. The participants were also asked
whether they considered themselves to be Spanish/Hispanic/Latino.
Those who identified themselves as primarily ‘White’ or ‘Black’ were
eligible to participate. The study participants included 186 blacks,
three of whom considered themselves to also be Hispanics, and the
147 whites including 8 who considered themselves to also be
Hispanic.
Subjects could be either normotensive or mildly hypertensive.
Hypertension status was defined as an average clinic BP X140/
90 mm Hg at recruitment or being on antihypertensive medication.
Individuals taking medication were withdrawn successfully from
medication for at least 2 weeks prior to the study. Those whose BP
exceeded 160/105 mm Hg, before or after being withdrawn from
medication, were not eligible.
Blood pressure measurements
Blood pressure measurements were made by trained research
personnel using a mercury sphygmomanometer according to the
American Heart Association Guidelines, with patients seated and
arm at heart level.45 Three readings were obtained and their average
was recorded as the clinic blood pressure measure.
Laboratory tests
All subjects were on ad libitum diet. All laboratory tests were
performed with the biologic specimens collected at the same time,
and at the time clinical blood pressure measurements were made.
The specimens were collected by a minimum of two-weeks following
the withdrawal from antihypertensive medications. Prior to with-
drawal, 10 of the 70 black hypertensives and 11 of the 68 white
hypertensives were on either angiotensin-converting inhibitor or
angiotensin II receptor blocker.
PRA was measured using an enzyme-based method and by
quantification of generated Ang I by radioimmunoassay.46
Twenty-four-hour urine collections were analyzed by the Weill
Cornell Medical College General Clinical Research Center for
sodium, creatinine, and albumin. Urinary albumin and creatinine
concentrations were calculated using Bayer’s DCA 2000 micro-
albumin/creatinine low and High Control Kit with the company’s
DCA 2000þ Analyzer. If the albumin result was o5 mg/l, the
lowest limit of detection, the concentration calculated from
Diagnostic Product Corporation’s radioimmunoassay kit was used.
Microlbuminuria was defined as an albumin/creatinine ratio
430 mg/gm.
TGF-b1 protein measurement
Peripheral venous blood was obtained from the study participants
and serum was isolated and stored at 701C until assayed for TGF-
b1 protein. Serum TGF-b1 protein concentration was measured
using an isoform-specific TGF-b1 ELISA according to the
manufacturer’s protocol (Quantikine Human TGF-b1 Immunoas-
say, R&D Systems Inc. Minneapolis, MN, USA). Total TGF-b1 levels
were measured after acid activation (acetic acid/urea) and
neutralization (NaOH/HEPES) of serum from all 333 subjects.
Active TGF-b1 (serum assayed without the activation step) was
measured in all 147 available sera from the 333 subjects. A TGF-b1
standard curve was constructed by using 2000, 1000, 500, 250, 125,
62.50, 31.25 pg/ml recombinant TGF-b1 protein, and a curve-fitting
software program was used to quantify TGF-b1 protein concentra-
tion in the sera. The minimum detectable level is 7.0 pg/ml and the
intra-assay and inter-assay median coefficients of variation are
reported to be 5.3 and 10.9%, respectively.
Definition of metabolic syndrome
Metabolic syndrome was defined according to the current
recommended criteria of the National Cholesterol Education
Program (Adult Treatment Panel (ATP) III).20
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Statistical analysis
Descriptive statistics are reported as percentages for binary/
categorical measures or means and s.d. for continuous measures;
the median and quartiles are also reported for severely skewed
measures. Regression analyses were used to estimate and test the
relationship of serum TGF-b1 protein concentrations to PRA, blood
pressure, urinary sodium excretion, BMI, microalbuminuria, and
MBS; linear regression for the continuous outcome measures,
logistic regression for the binary measures, and ordered probit
regression for the number of metabolic syndrome criteria measure
(an ordinal categorical measure ranging from 0 to 5). PRA was
transformed to natural logarithms to reduce skewness and
heteroskedasticity. For all regression analyses, the TGF-b1 protein
measure was transformed using the square root transformation to
reduce the positive skewness and make the resulting distribution
approximately symmetric and normal. Regression estimates are
reported as the predicted difference in the outcome between
someone at the 90th percentile and someone at the 10th percentile
of the TGF-b1 distribution. All analyses were performed on the full
sample, with and without the inclusion of a multiplicative race-by-
TGF-b1 interaction term. The inclusion of this interaction term
yielded separate estimates for blacks and whites of the effect of
TGF-b1, and a test of the black–white difference. Sex and age were
statistically controlled for in all analyses, and BMI was controlled
when predicting all outcomes except BMI and metabolic syndrome.
For the continuous outcome measures, we also estimated LOESS
models for blacks and whites, to detect any non-linear relationships.
None were found and therefore the results of the LOESS models are
not presented.
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